CONVINCE trial reveals the effect of long-term colchicine on recurrent stroke and cardiovascular events

FHS
May 16, 2024
5:39 pm

In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organisation Conference (ESOC) 2024, anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke in the primary intention-to-treat analysis.

Mini-summit to address how informatics can help resolve health effects of climate change

Regenstrief Institute, the International Medical Informatics Association (IMIA), the International Academy of Health Sciences Informatics (IAHSI) and the American Medical Informatics Association (AMIA) are hosting

November 11, 2023

AbbVie looks to add an eighth indication for JAK inhibitor Rinvoq

Rinvoq is one of the top revenue-generating therapies for AbbVie, raking in approximately $4bn in sales last year, per the company’s financials. Image Credit: Skorzewiak

July 15, 2024

Opinion | Hello Buprenorphine, Step Into My Practice

Wakeman is an addiction medicine specialist and an associate professor of medicine. After years of alarming increases in opioid overdose deaths, the U.S. finally saw

December 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.